Simplify Logo

Full-Time

Associate Director

TMF Management & Inspection Readiness

Confirmed live in the last 24 hours

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

501-1,000 employees

Develops therapies for neurological disorders

Biotechnology
Healthcare

Compensation Overview

$144k - $180.5kAnnually

+ Bonus + Equity Awards

Senior, Expert

San Diego, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Management
Requirements
  • Bachelor’s degree in the life sciences or related field; Advanced degree preferred.
  • Targeting at least 8 years pharmaceutical industry and/or clinical research organization experience, with at least 4 years TMF experience in a leadership and oversight role.
  • Health Authority inspection experience is required.
  • Thorough understanding of GCP and ICH guidelines; thorough understanding of the drug development process.
  • Knowledge and understanding of the current regulatory requirements (e.g., FDA, EMA, MHRA) in a global environment.
  • Thorough understanding of the CDISC TMF Reference model; direct experience with the TMF Reference Model working group is preferred.
  • eTMF experience required; Veeva Vault eTMF/CTMS experience preferred.
  • Demonstrated problem-solving abilities, with strong attention to detail.
  • Adept at creating and communicating a clear vision among direct reports, effectively aligning resources and motivating stakeholders to achieve goals.
  • Demonstrated analytical abilities and proficient planning and negotiation skills.
  • Strong interpersonal, organizational and workload planning skills along with excellent verbal and written communication skills.
  • Demonstrated success with cross-functional collaboration and managing multiple assignments with timely and accurate output.
  • Demonstrated technical, administrative, and project management capabilities.
  • Ability to travel approximately 25% of the time.
Responsibilities
  • Is responsible for resource planning, including consultants, to support TMF and inspection readiness including TMF management vendor to ensure compliance with GCP and industry standards.
  • Provide leadership and oversight for the Trial Master File (TMF) process, including the TMF related controlled documents/templates, ensuring compliance with regulatory requirements and organizational standards.
  • Review TMF metrics across programs, analyzing TMF performance indicators and identifying trends or deviations from Key Performance Indicators (KPIs).
  • Escalate any TMF metrics falling outside of KPIs to appropriate stakeholders for resolution and corrective action.
  • Serve as a key point of contact for TMF-related inquiries and provide SME guidance to internal stakeholders on TMF processes and requirements.
  • Lead the development and maintenance of comprehensive inspection readiness plans, tools, reference materials, and provide guidance to staff on preparation efforts for health authority inspections.
  • Support Clinical Operations team on all inspection commitments, responses, post-inspection activities and implementation of corrective and preventative actions; provide lessons learned from mock and actual inspections.
  • Assist the liaison between Acadia and regulatory agencies, facilitating communication and information exchange during inspections and providing leadership to staff in inspection preparation and response strategies.
  • Lead and share TMF best practices with internal and external stakeholders, as appropriate.
  • Maintain awareness of industry trends and developments to help define the future strategic direction for TMF and Inspection Readiness.
  • Other responsibilities as required.
Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. Their products are created through extensive research and development, followed by rigorous clinical trials to ensure safety and effectiveness. Once approved by regulatory bodies like the FDA, these therapies are marketed to patients and healthcare providers. Acadia stands out from competitors by concentrating on areas with significant unmet medical needs and fostering strategic partnerships to enhance their research and market presence. The company's goal is to improve the quality of life for individuals with neurological conditions through effective treatments.

Company Stage

IPO

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals Inc. unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.